Opiant Pharmaceuticals, Inc. (“Opiant” or “Company”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today announced it will report its financial results for the second quarter ended June 30, 2022, after the financial markets close on Thursday, August 11, 2022.
SANTA MONICA, Calif., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant” or “Company”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today announced it will report its financial results for the second quarter ended June 30, 2022, after the financial markets close on Thursday, August 11, 2022.
The Company’s management team is scheduled to host a conference call and webcast at 4:30 p.m. ET on Thursday, August 11, 2022. To access the call, please dial 1-877-407-0792 in the U.S. or 1-201-689-8263 outside the U.S. and provide the conference ID number: 13730815. To access the live webcast, please visit https://viavid.webcasts.com/starthere.jsp?ei=1556372&tp_key=6cb19180df. Following the live webcast, an archived version of the call will be available on the website.
Thursday August 11 @ 4:30 pm ET
| Domestic: | 1-877-407-0792 |
| International: | 1-201-689-8263 |
| Conference ID: | 13730815 |
| Webcast: | https://viavid.webcasts.com/starthere.jsp?ei=1556372&tp_key=6cb19180df |
About Opiant Pharmaceuticals, Inc.
Opiant Pharmaceuticals, Inc., the company that developed NARCAN® Nasal Spray, is building a leading franchise of new medicines to combat addictions and drug overdose. For more information visit: www.opiant.com.
For Media and Investor Inquiries:
Ben Atkins, Opiant
(310) 598-5410
batkins@opiant.com
